“A showcase of what is going on in prostate cancer in Europe”

18 June 2019

“PCa 19 will provide an in-depth and critical assessment of standard, innovative and prospective PCa therapies,” says Prof. Jeroen van Moorselaar (Amsterdam, NL). “To achieve this, we’ve pooled the expertise of prostate cancer specialists from various European countries and faculty members of the European School of Urology (ESU) and organised a two-day programme which covers a whole array of topics in PCa management.”

Prof. Van Moorselaar sits on the PCa19 Scientific Committee, and has been involved in making the scientific programme since PCa18. Speakers and tutors are coming from every PCa-related experise: “The whole field of prostate cancer treatment is covered. We are very happy that so many experts in the field will come to Prague.”

Over the past few years, the EAU has introduced a series of meetings beyond the traditional Section Meetings, which follow subspecialties of urology (Onco-urology, Robtotic Urology, Urolithiasis, etc). The new Oncology Update series started in 2017 with the first PCa Update in Vienna, leading to more topic-based, educational updates that involve speakers from several backgrounds and EAU Sections. In its wake, BCa and RCC Updates followed.

Critical assessment

In presenting this critical assessment and updating the audience, PCa19 offers an interactive and educationally-oriented scientific programme. Van Moorselaar: “A large part of the programme will be the case discussions, which will stimulate discussions among the participants.”

“Through this we understand how to implement the guidelines in daily practice and appreciate differences among the countries in Europe.”

Van Moorselaar sees the most important topics at PCa19 as the new imaging possibilities that are available to specialists, such as MRI and PSMA-PET scanning. “New treatment options are available for metastatic hormone sensitive prostate cancer, but also for non-metastatic castration resistant prostate cancer. Furthermore very interesting is the field of treatment of oligometastatic disease.”

Prof. Van Moorselaar is also taking part in the scientific programme: “I will be chairing a session on focal therapy. Although the EAU Guidelines state that focal therapy is still experimental, many new data with longer follow-up show interesting results. An important part of the discussion should be about the comparison to active surveillance.”

Urologists should familiarise themselves with new developments in PCa treatment, as they are essential in the multidisciplinary future. Van Moorselaar: “As the programme shows, the treatment of prostate cancer is typically a case for a multidisciplinary team of urologists, radiation oncologists, nuclear medicine specialists, pathologists and medical oncologists. The urologist has the initial contact with the patient and makes the diagnosis. In a large team you need a leader or chairman and this is the urologist.”